PegBio Co

PegBio Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of PegBio Co (2565.HK) as of Nov 18, 2026 is 82.42 M CNY. In the previous year, Stock-Based Compensation (SBC) was 145.47 M CNY — a change of -43.34% (lower).

Stock-Based Compensation

82.42 MCNY

YoY

-43.34%

Last updated:

Stock-Based Compensation (SBC) of PegBio Co is 2025 82.42 M CNY. Stock-Based Compensation (SBC) of PegBio Co was 2024 145.47 M CNY. It decreases by -43.34% lower compared to the previous year.

The PegBio Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2022
22.97 M CNY
Jan 1, 2023
35.11 M CNY
Jan 1, 2024
145.47 M CNY
Jan 1, 2025
82.42 M CNY
The PegBio Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
82.42 MCNY-43.34%
145.47 MCNY+314.29%
35.11 MCNY+52.84%
22.97 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Stock-Based Compensation (SBC) of PegBio Co is 82.42 M CNY in 2025.

Stock-Based Compensation (SBC) of PegBio Co changed from 145.47 M CNY to 82.42 M CNY, representing a -43.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) PegBio Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s PegBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PegBio Co

All Key Metrics — PegBio Co